On October 20, 2016 Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, reported that the Company has been selected for two poster presentations on its Antibody-Coupled T-Cell Receptor (ACTR) platform at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Tumor Immunology and Immunotherapy 2016 Meeting (Press release, Unum Therapeutics, OCT 20, 2016, View Source [SID1234515935]). The conference will take place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, MA.
Presentation Details:
Presentation Title: Efficient targeting of HER‐2‐positive cancers by Antibody‐Coupled T cell Receptor (ACTR) engineered autologous T cells
Presenter: Casey B. Judge
Presentation Date: Friday, October 21, 2016
Presentation Time: 5:15 p.m.‐7:45 p.m.
Room: Back Bay Room
Abstract Number: A77
Presentation Title: High throughput triage of the ACTR platform demonstrates broad activity across multiple tumor targets
Presenter: Eugene Choi
Presentation Date: Saturday, October 22, 2016
Presentation Time: 6:00 p.m.‐8:45 p.m.
Room: Back Bay Room
Abstract Number: B60
The posters will be posted on Unum’s website following the presentations.
About Antibody-Coupled T-cell Receptor (ACTR) Technology and ACTR087
Unum’s proprietary ACTR is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T-cells – to create a novel cancer cell killing activity. T-cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.
In contrast to other T-cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody.
Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum’s most advanced product candidate, combines Unum’s proprietary ACTR, with rituximab, an anti-CD20 antibody. The ACTR087 study will be the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patient T-cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!